Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00195442
Status:
COMPLETED
Last Update Posted:
2011-02-11
First Post:
2005-09-13
Brief Title:
Study Evaluating Refacto For Pharmacovigilance
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
Pharmacovigilance Evaluation Of Refacto In Usual Care Settings
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy Furthermore a continuous benefitrisk assessment will be done
Detailed Description:
Non-interventional study subjects to be selected according to the usual clinical practice of their physician
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None